J Am Pharm Assoc (2003). 2014 Jan-Feb;54(1):27-34. doi: 10.1331/JAPhA.2014.13083.
OBJECTIVES To assess changes in prescription gross margin from 2008 to 2011 using a random sample of prescriptions, analyze changes in prescription gross margin from 2008 to 2011 using a market basket of prescription drugs, and investigate impact of changes in prescription mix from 2008 to 2011 on prescription gross margins. DESIGN Longitudinal, retrospective, descriptive case study. SETTING Single independent pharmacy in Iowa City, IA, from March and April of 2008-11. PARTICIPANTS Prescription dispensing records for the pharmacy's largest private and Part D payers by prescription volume, as well as Medicaid and cash payers. INTERVENTION Random sampling and market basket approaches were used for gross margin calculation. MAIN OUTCOME MEASURES Prescription gross margins and generic dispensing rate. RESULTS Data were collected for 2,400 prescription records for the random sample and 4,860 prescriptions for the market basket sample. The median random sample and market basket gross margin dollars (GMDs) from 2008 to 2011 decreased from $9.55 to $7.22 and from $9.60 to $8.50, respectively. The percent of dispensed prescriptions that was generic increased from 62.65% in 2008 to 73.64% in 2011, and GMDs were significantly lower for generic products. CONCLUSION Third-party prescription drug gross margins in the study pharmacy varied substantially by payer and decreased over time. Pharmacies must continue to monitor changes in prescription margins and investigate ways to enhance alternative revenue sources to maintain profitability.
目的 :使用随机抽样处方评估 2008 年至 2011 年处方毛利的变化,分析 2008 年至 2011 年处方药篮子的处方毛利变化,并调查 2008 年至 2011 年处方组合变化对处方毛利的影响。
设计 :纵向、回顾性、描述性病例研究。
地点 :爱荷华市的一家独立药房,时间为 2008 年 3 月至 4 月至 2011 年。
参与者 :按处方量,该药房最大的私人和部分 D 支付者以及医疗补助和现金支付者的处方配药记录。
干预措施 :使用随机抽样和市场篮子方法计算毛利。
主要观察指标 :处方毛利和仿制药配药率。
结果 :随机样本收集了 2400 张处方记录,市场篮子样本收集了 4860 张处方。2008 年至 2011 年,随机样本和市场篮子的中位数毛利(GMD)从 9.55 美元降至 7.22 美元,从 9.60 美元降至 8.50 美元。2008 年至 2011 年,处方中仿制药的比例从 62.65%增加到 73.64%,而 GMD 对于仿制药则明显较低。
结论 :研究药房的第三方处方药毛利因支付者而异,且随时间推移而降低。药房必须继续监测处方利润率的变化,并调查增强替代收入来源的方法,以维持盈利能力。